Sol-Gel Technologies (SLGL) Liabilities and Shareholders Equity (2016 - 2026)
Sol-Gel Technologies' (SLGL) quarterly Liabilities and Shareholders Equity came in at $58.6 million in Q1 2026, up 116.35% year-on-year from $27.1 million in Q1 2025, and up 95.71% on a QoQ basis from $29.9 million in Q4 2025.
Sol-Gel Technologies (SLGL) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $58.6 million in Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 116.35% year-over-year to $58.6 million in Q1 2026; TTM through Mar 2026 was $162.4 million, a 9.79% increase from a year earlier, with the FY2025 full-year figure at $29.9 million, down 16.54% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $58.6 million, up from $29.9 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for SLGL reached as high as $58.6 million in Q1 2026 and fell as low as $27.1 million in Q1 2025.
- Historically, Liabilities and Shareholders Equity has averaged $44.6 million across 5 years, with a median of $45.3 million in 2023.
- Across the five-year window, Liabilities and Shareholders Equity plunged 32.61% in 2022 and surged 116.35% in 2026, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $46.6 million in 2022, then dropped by 2.88% to $45.3 million in 2023, then retreated by 20.85% to $35.8 million in 2024, then slipped by 16.54% to $29.9 million in 2025, then soared by 95.71% to $58.6 million in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $58.6 million in Q1 2026, $29.9 million in Q4 2025, and $34.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Sol-Gel Technologies | 227.58 Mn | 217.44 Mn | - | 58.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.55 Mn |
| Dec 31, 2025 | 29.92 Mn |
| Sep 30, 2025 | 34.59 Mn |
| Jun 30, 2025 | 39.31 Mn |
| Mar 31, 2025 | 27.06 Mn |
| Dec 31, 2024 | 35.85 Mn |
| Sep 30, 2024 | 42.98 Mn |
| Jun 30, 2024 | 42.01 Mn |
| Mar 31, 2024 | 39.91 Mn |
| Dec 31, 2023 | 45.29 Mn |
| Sep 30, 2023 | 49.86 Mn |
| Jun 30, 2023 | 55.10 Mn |
| Mar 31, 2023 | 49.04 Mn |
| Dec 31, 2022 | 46.63 Mn |
| Sep 30, 2022 | 51.29 Mn |
| Jun 30, 2022 | 54.98 Mn |
| Mar 31, 2022 | 56.06 Mn |
| Dec 31, 2021 | 69.19 Mn |
| Sep 30, 2021 | 52.83 Mn |
| Jun 30, 2021 | 46.41 Mn |